The UK biotechnology sector has failed to deliver and its credibility has been weakened by plunging share prices, slow drug development and investor scepticism, according to a report by Seymour Pierce, the broker.

Zhining Xu, an analyst at Seymour Pierce, said the poor state of the credit markets and general negative sentiment had meant last year was a “disaster for biotechnology in the UK”.